Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
| 5.06 | |
| 5.36 | |
| - | |
| 5.41 | |
| 5.04 | |
| 3.8-7.91 | |
| 692 M | |
| 131 M | |
| 21 021 K | |
| -0.36 | |
| 0.843 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
We recently compiled a list of the 35 Trending AI Stocks on Latest News and Analyst Ratings.In this article, we are going to take a look at where Exscientia plc (NASDAQ:EXAI) stands against the other ...
Recursion Pharmaceuticals(NASDAQ: RXRX) and Exscientia(NASDAQ: EXAI) made waves on Aug. 8 when they announced plans to merge into one business, forming the world's largest biotech devoted to doing dru...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
